331 related articles for article (PubMed ID: 22095519)
1. Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates.
Samuele A; Bisi S; Kataropoulou A; La Regina G; Piscitelli F; Gatti V; Silvestri R; Maga G
Antivir Chem Chemother; 2011 Nov; 22(3):107-18. PubMed ID: 22095519
[TBL] [Abstract][Full Text] [Related]
2. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
[TBL] [Abstract][Full Text] [Related]
3. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
[TBL] [Abstract][Full Text] [Related]
4. Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants.
Butini S; Gemma S; Brindisi M; Borrelli G; Fiorini I; Samuele A; Karytinos A; Facchini M; Lossani A; Zanoli S; Campiani G; Novellino E; Focher F; Maga G
Bioorg Med Chem Lett; 2011 Jul; 21(13):3935-8. PubMed ID: 21636271
[TBL] [Abstract][Full Text] [Related]
5. Substrate-induced stable enzyme-inhibitor complex formation allows tight binding of novel 2-aminopyrimidin-4(3H)-ones to drug-resistant HIV-1 reverse transcriptase mutants.
Samuele A; Facchini M; Rotili D; Mai A; Artico M; Armand-Ugón M; Esté JA; Maga G
ChemMedChem; 2008 Sep; 3(9):1412-8. PubMed ID: 18465760
[TBL] [Abstract][Full Text] [Related]
6. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
Rodríguez-Barrios F; Gago F
J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
[TBL] [Abstract][Full Text] [Related]
7. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
[TBL] [Abstract][Full Text] [Related]
8. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
[TBL] [Abstract][Full Text] [Related]
9. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
[TBL] [Abstract][Full Text] [Related]
10. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.
Maga G; Amacker M; Ruel N; Hübscher U; Spadari S
J Mol Biol; 1997 Dec; 274(5):738-47. PubMed ID: 9405155
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Ma XD; Zhang X; Dai HF; Yang SQ; Yang LM; Gu SX; Zheng YT; He QQ; Chen FE
Bioorg Med Chem; 2011 Aug; 19(15):4601-7. PubMed ID: 21719299
[TBL] [Abstract][Full Text] [Related]
12. New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Brancale A; Piscitelli F; Famiglini V; Cosconati S; Maga G; Samuele A; Gonzalez E; Clotet B; Schols D; Esté JA; Novellino E; Silvestri R
J Med Chem; 2012 Jul; 55(14):6634-8. PubMed ID: 22712652
[TBL] [Abstract][Full Text] [Related]
13. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
Regina GL; Coluccia A; Piscitelli F; Bergamini A; Sinistro A; Cavazza A; Maga G; Samuele A; Zanoli S; Novellino E; Artico M; Silvestri R
J Med Chem; 2007 Oct; 50(20):5034-8. PubMed ID: 17803291
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives.
Ranise A; Spallarossa A; Cesarini S; Bondavalli F; Schenone S; Bruno O; Menozzi G; Fossa P; Mosti L; La Colla M; Sanna G; Murreddu M; Collu G; Busonera B; Marongiu ME; Pani A; La Colla P; Loddo R
J Med Chem; 2005 Jun; 48(11):3858-73. PubMed ID: 15916438
[TBL] [Abstract][Full Text] [Related]
15. Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
La Regina G; Coluccia A; Brancale A; Piscitelli F; Gatti V; Maga G; Samuele A; Pannecouque C; Schols D; Balzarini J; Novellino E; Silvestri R
J Med Chem; 2011 Mar; 54(6):1587-98. PubMed ID: 21366296
[TBL] [Abstract][Full Text] [Related]
16. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
17. New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
Famiglini V; La Regina G; Coluccia A; Pelliccia S; Brancale A; Maga G; Crespan E; Badia R; Clotet B; Esté JA; Cirilli R; Novellino E; Silvestri R
Eur J Med Chem; 2014 Jun; 80():101-11. PubMed ID: 24769348
[TBL] [Abstract][Full Text] [Related]
18. Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
Butini S; Brindisi M; Cosconati S; Marinelli L; Borrelli G; Coccone SS; Ramunno A; Campiani G; Novellino E; Zanoli S; Samuele A; Giorgi G; Bergamini A; Di Mattia M; Lalli S; Galletti B; Gemma S; Maga G
J Med Chem; 2009 Feb; 52(4):1224-8. PubMed ID: 19170521
[TBL] [Abstract][Full Text] [Related]
19. High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.
Cancio R; Silvestri R; Ragno R; Artico M; De Martino G; La Regina G; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
Antimicrob Agents Chemother; 2005 Nov; 49(11):4546-54. PubMed ID: 16251294
[TBL] [Abstract][Full Text] [Related]
20. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
